Frontiers in Cardiovascular Medicine

FEBRUARY 10, 2025

BackgroundAbdominal aortic calcification (AAC), an early indicator of abdominal aortic wall atherosclerosis, is a marker of subclinical atherosclerosis and a predictive factor for vascular-associated morbidity and mortality. These outcomes are driven by inflammatory processes.

Aortic 52

Aortic Atherosclerosis Laboratory Biomarkers 52

Frontiers in Cardiovascular Medicine

APRIL 24, 2024

The early detection of plaques by circulating biomarkers is highly clinically relevant to prevent the occurrence of major complications such as stroke or heart attacks. BackgroundAtherosclerosis is a widespread disorder of the cardiovascular system. EVs were isolated from serum by precipitation.

Plaque 52

Plaque Biomarkers Circulation Stenosis 52

Cardiovascular Diabetology

JANUARY 8, 2024

Atherosclerosis is one of the leading causes of death worldwide. miR-26 is a potential biomarker of atherosclerosis. Standardized diagnostic tests for miR-26 (MIR26-DX) have been developed, but the fastest pro.

Atherosclerosis 52

Atherosclerosis Biomarkers 52

DAIC

FEBRUARY 1, 2024

February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, DAIC has compiled a snapshot of significant cardiovascular disease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market. percent Compound Annual Growth Rate (CAGR).

Cardiovascular Disease 104

Cardiovascular Disease Atherosclerosis Peripheral Arterial Disease Stroke 104

Frontiers in Cardiovascular Medicine

JULY 2, 2024

It is proven challenging managing chronic cardiovascular illnesses like atherosclerosis, arrhythmias, and diverse cardiomyopathies. In this case, because the risk of cardiac events correlates with the QT prolongation rates, the QT or QTc interval prolongation has become an important biomarker to access drug-related cardio-toxicity.

Atherosclerosis 52

Atherosclerosis Cardiovascular Disease Physiology Biomarkers 52

Frontiers in Cardiovascular Medicine

OCTOBER 13, 2024

ObjectiveThe present study aimed at evaluating the association between sympathetic nervous system activation (SNS) and the severity of coronary artery disease (CAD).

Coronary Artery Bypass Graft 52

Coronary Artery Bypass Graft Atherosclerosis Biomarkers Coronary Artery Disease 52

DAIC

FEBRUARY 3, 2025

This clearance comes in advance of disease-modifying therapies on the horizon expected to help clinicians use this biomarker to guide patients to improved cardiovascular health, saidBrad Moore, president and CEO at Roche Diagnostics North America. The development of the Tina-quant Lipoprotein (a) Gen.2 2022 Aug, 80 (9) 934946 Kronenberg F.

Cardiovascular Disease 52

Cardiovascular Disease Aortic valve Biomarkers Innovation 52

Stroke Journal

FEBRUARY 1, 2024

Background:Ischemic stroke can arise from various etiologies, such as cardioembolism, atherosclerosis, small vessel disease or cryptogenic. IL-2Rα levels were significantly elevated in patients with ischemic stroke due to large-artery atherosclerosis (53.5±4.7 Stroke, Volume 55, Issue Suppl_1 , Page ATP245-ATP245, February 1, 2024.

Biomarkers 40

Biomarkers Stroke Strokes Atherosclerosis 40

Open Heart

MAY 31, 2022

Background Hepatocyte growth factor (HGF) is a biomarker with potential for use in the diagnosis, treatment and prognostication of cardiovascular disease (CVD). Methods At baseline, adults aged 45–84 years, free of CVD, in the Multi-Ethnic Study of Atherosclerosis had HGF and ECC measured by ELISA and cardiac CT scan, respectively.

Atherosclerosis 52

Atherosclerosis Aortic valve Risk Factors Aortic 52

Cardiovascular Diabetology

FEBRUARY 14, 2025

The Systemic Immune-Inflammation Index (SII) is a novel biomarker of systemic inflammation. We explored the association between the SII and metabolic syndrome (MetS) and its components in middle-aged and older.

Atherosclerosis 52

Atherosclerosis Biomarkers Research 52

Frontiers in Cardiovascular Medicine

JULY 17, 2024

The triglyceride–glucose (TyG) index, proven to be a crucial insulin resistance biomarker (better than the Homeostasis Model Assessment for Insulin Resistance), is simple and non-invasive.

Heart Failure 64

Heart Failure Atherosclerosis Biomarkers Obesity 64

Cardiovascular Diabetology

FEBRUARY 19, 2024

The triglyceride-glucose (TyG) index is considered a dependable biomarker for gauging insulin resistance. The atherogenic index of plasma (AIP) represents a marker reflecting atherosclerosis. However, there is.

Coronary Artery Disease 52

Coronary Artery Disease Atherosclerosis Biomarkers Research 52

DAIC

JANUARY 23, 2024

1,6 Until recently atherosclerosis has been thought of as the result of passive lipid accumulation in the vessel wall. However, the development of atherosclerosis is now known to be much more complex, with a key role for immune cells and inflammation in conjunction with hyperlipidemia and elevated LDL levels.7

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Frontiers in Cardiovascular Medicine

AUGUST 7, 2024

This article evaluates the utility of S100A8/A9 protein as a biomarker and therapeutic target for diagnosing cardiovascular diseases, considering its structural features, fundamental biological properties, and its multifaceted influence on cardiovascular conditions including atherosclerosis, myocardial infarction, myocardial ischemia/reperfusion injury, (..)

Cardiovascular Disease 52

Cardiovascular Disease Myocardial Infarction Atherosclerosis Article 52

Frontiers in Cardiovascular Medicine

JUNE 3, 2024

Multiple metabolites of KP have been observed to exhibit elevated concentrations in plasma across various cardiovascular diseases, such as atherosclerosis, hypertension, and acute myocardial infarction. Multiple studies have indicated that kynurenine (KYN) may serve as a potential biomarker for several adverse cardiovascular events.

Cardiovascular Disease 52

Cardiovascular Disease Atherosclerosis Myocardial Infarction Physiology 52

Heart BMJ

SEPTEMBER 25, 2024

Background Integration of large proteomics and genetic data in population-based studies can provide insights into discovery of novel biomarkers and potential therapeutic targets for cardiometabolic diseases (CMD). There were 245 potentially causal protein biomarkers identified in MR pooled results, involving 23 pleiotropic proteins.

Circulation 52

Circulation Biomarkers Heart Failure Atrial Fibrillation 52

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

IntroductionIntracranial atherosclerosis‐related large vessel occlusion (ICAS‐LVO) is a common cause of failed mechanical thrombectomy (MT) in acute ischemic stroke (AIS) [1]. Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023.

Atherosclerosis 40

Atherosclerosis Angioplasty Stents Stent 40

Circulation

NOVEMBER 11, 2024

Background:Peripheral artery disease (PAD) is associated with high morbidity and mortality and is closely related to diabetes mellitus (DM) and atherosclerosis. These findings suggest that VTRNA2-1 promoter methylation status could serve as a valuable biomarker for predicting prognosis and guiding treatment strategies in PAD.

Peripheral Arterial Disease 40

Peripheral Arterial Disease Biomarkers Angioplasty Atherosclerosis 40

Stroke: Vascular and Interventional Neurology

JANUARY 25, 2024

Stroke: Vascular and Interventional Neurology, Ahead of Print. Fear of hemorrhagic complications (74%) was the most compelling reason not to perform RS±angioplasty.

Atherosclerosis 40

Atherosclerosis Angioplasty Stenosis Stent 40

Stroke Journal

FEBRUARY 1, 2024

Background:The association between left ventricular injury (LVI) detected by cardiac magnetic resonance imaging (CMR) and the risk of a subsequent ischemic stroke is unknown.Methods:We studied stroke-free participants in the Multi-Ethnic Study of Atherosclerosis study who underwent a steady-state free precession CMR at Exam 5 (2010-2012).

Atherosclerosis 40

Atherosclerosis Stroke Strokes Atrial Fibrillation 40

Open Heart

MARCH 24, 2023

The pathophysiology of calcific AS (CAS) is complex, yet can be characterised similarly to that of atherosclerosis. Novel approaches are developing to address this through: (1) screening with circulating biomarkers; (2) development of drugs to slow disease progression and (3) early valve intervention guided by medical imaging.

Stenosis 52

Stenosis Aortic Aortic valve Biomarkers 52

Circulation

JANUARY 15, 2024

Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Circulation, Volume 149, Issue 3 , Page 251-266, January 16, 2024. Nevertheless, the relationship between CAC and the susceptibility of a plaque to provoke a thrombotic event remains incompletely understood.

Coronary Artery Disease 45

Coronary Artery Disease Atherosclerosis Laboratory Plaque 45

Cardiometabolic Health Congress

OCTOBER 25, 2024

Keynote speaker and atherosclerosis expert Peter Libby, MD , captivated the audience with an update on his research into inflammation and atherosclerosis. He discussed therapeutic options not only for treating atherosclerosis but also for preventing cardiovascular disease.

CME 64

CME Innovation Education Atherosclerosis 64

Open Heart

DECEMBER 9, 2022

Endothelial dysfunction (ED) has a substantial role in the pathogenesis of atherosclerosis and other vascular diseases. Peripheral vascular techniques and endothelial biomarkers can be used to indirectly assess coronary ED.

Atherosclerosis 40

Atherosclerosis Biomarkers Risk Factors Diabetes 40

European Journal of Heart Failure

NOVEMBER 3, 2024

Aims Abnormalities in specific echocardiographic parameters and cardiac biomarkers have been reported among individuals with diabetes. In this study, we developed and validated a machine learning-based clustering approach to identify the high-risk DbCM phenotype based on echocardiographic and cardiac biomarker parameters.

Cardiomyopathy 40

Cardiomyopathy Diabetes Biomarkers Atherosclerosis 40

Frontiers in Cardiovascular Medicine

MARCH 4, 2024

The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional risk factors. Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide.

Plaque 59

Plaque Coronary Artery Disease Blood Pressure Cardiovascular Disease 59

Cardiometabolic Health Congress

JULY 25, 2024

The stage will host internationally acclaimed atherosclerosis visionary Peter Libby, MD , as the keynote speaker; preventive cardiology and women’s health expert Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC ; famed hypertension expert Keith C.

Education 100

Education Innovation Risk Factors Obesity 100

Stroke: Vascular and Interventional Neurology

JUNE 20, 2024

While traditional vascular risk factors (eg, hypertension, dyslipidemia, tobacco use) account for 20% of the explained variance in carotid atherosclerosis, they remain a prominent focus for primary and secondary ischemic stroke prevention strategies. Stroke: Vascular and Interventional Neurology, Ahead of Print.

Cerebrovascular Disease 40

Cerebrovascular Disease Atherosclerosis Atrial Fibrillation Physiology 40

Circulation

NOVEMBER 11, 2024

Considering their multidirectional effect on atherosclerosis, new inflammatory biomarkers integrating various leukocyte subgroups have been proposed to calculate the systemic inflammatory response index (SIRI) and systemic inflammatory index (SII).Aim:The

Angina 40

Angina Coronary Artery Disease Biomarkers Atherosclerosis 40

Journal of Cardiovascular Pharmacology

SEPTEMBER 4, 2023

Dysregulation of the innate and adaptive immune system is accelerated by CKD and results in increased systemic inflammation, a heightened local vascular inflammatory response leading to accelerated atherosclerosis, and dysfunction of the cardiac and renal endothelium and microcirculation.

Kidney Disease 40

Kidney Disease Transplant Atherosclerosis Biomarkers 40

DAIC

JANUARY 30, 2024

The new model uses a set of 10 factors including age, cigarette smoking status, diabetes status, and blood levels of several cardiac biomarkers, to gauge the risk of a new cardiovascular event, regardless of whether the patient has had one before.

Cardiovascular Disease 52

Cardiovascular Disease Research Heart Attack Heart attacks 52

Circulation: Heart Failure

MARCH 1, 2024

Identifying novel biomarkers can help in understanding HF pathogenesis and improve at-risk population identification. Circulation: Heart Failure, Ahead of Print. BACKGROUND:Older adults have markedly increased risks of heart failure (HF), specifically HF with preserved ejection fraction (HFpEF).

Heart Failure 40

Heart Failure Preserved Ejection Fraction Risk Factors Atherosclerosis 40

Journal of the American Heart Association

JANUARY 19, 2024

BackgroundAortic stenosis has pathophysiological similarities with atherosclerosis, including the deposition of cholesterol‐containing lipoproteins. Journal of the American Heart Association, Ahead of Print. Although low‐density lipoprotein cholesterol levels were comparable in both groups (101.8±37.3 mg/dL versus 97.9±37.6

Aortic valve 40

Aortic valve Cholesterol Aortic Stenosis 40

Cardiometabolic Health Congress

AUGUST 8, 2024

Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g., Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g.,

Education 59

Education Cardiovascular Disease Kidney Disease Diabetes 59

All About Cardiovascular System and Disorders

DECEMBER 15, 2023

Though this effect has also been documented with statin therapy, monotherapy using PCSK9 inhibitors or ezetimibe have not been associated with similar reduction in biomarkers of inflammation. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. at 6 months compared to placebo.

Cholesterol 52

Cholesterol Myocardial Infarction Cardiovascular Disease Diabetes 52

Dr. Paddy Barrett

OCTOBER 31, 2023

They have the biomarker of risk but no evidence of the disease , even later in life when you would expect them to have it. When there is a history of early events, then the likelihood of a member of that family with an elevated Lp(a) having premature coronary atherosclerosis is high. Atherosclerosis. 2017 Jan;256:47-52.

Coronary Artery Disease 52

Coronary Artery Disease Heart Disease Atherosclerosis Cardiovascular Disease 52

Dr. Paddy Barrett

AUGUST 22, 2023

Share For those with defective LDL receptors, as seen in familial hyperlipidemia, APOB particles are not cleared effectively, and concentrations rise, causing atherosclerosis 4. Which increases the risk of atherosclerosis. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. 108.179564.

Cholesterol 52

Cholesterol Dementia Coronary Artery Disease Cardiovascular Disease 52